Drugs / Afabicin
Afabicin
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT03209648 | Jun → Aug 2017 | — | Debiopharm International SA | Completed | No outcome recorded |
| Phase 1 | NCT02726438 | Apr 2016 → Jun 2017 | disease of bone structure | Debiopharm International SA | Completed | No outcome recorded |
| Phase 1 | NCT02595203 | Nov → Dec 2015 | — | Debiopharm International SA | Completed | No outcome recorded |
| Phase 1 | NCT02214433 | Aug 2014 → Feb 2015 | bacterial infectious disease | Debiopharm International SA | Completed | No outcome recorded |
| Phase 1 | NCT02162199 | Jun → Oct 2014 | bacterial infectious disease | Debiopharm International SA | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT03723551 | Feb 2019 → Apr 2025 | bacterial infectious disease | Debiopharm International SA | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT02426918 | May 2015 → Aug 2016 | bacterial infectious disease | Debiopharm International SA | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT07758608 Comparator | Sep 2026 → Dec 2027 expected | impaired renal function disease | Debiopharm International SA | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2014-09-04 | Debiopharm International SA | Regulatory Debiopharm Group™’s innovative antibiotic Debio1450 – developed from its proprietary plateform Fabiotics – Receives Qualified Infectious Disease Product (QIDP) Designation from the FDA debiopharm.com ↗
today announced that the US Food and Drug Administration (FDA) has designated its anti-infectious agent Debio1450 as a Qualified Infectious Disease Product (QIDP) |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-02-26 | Debiopharm International SA | Debiopharm International SA Initiates a Clinical Trial Phase II study evaluating afabicin in Bone and Joint Infections debiopharm.com ↗ |
| 2014-09-04 | Debiopharm International SA | Debiopharm Group™’s innovative antibiotic Debio1450 – developed from its proprietary plateform Fabiotics – Receives Qualified Infectious Disease Product (QIDP) Designation from the FDA debiopharm.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Afabicin | “Afabicin (formerly Debio 1450, AFN-1720) is a prodrug of afabicin desphosphono (Debio 1452, AFN-1252), a novel antibiotic in development which targets the staphylococcal...” PMID 30559136 ↗ Feb 20193“Afabicin (formerly Debio 1450, AFN-1720) is a prodrug” PMID 32747361 ↗ Sep 2020 |
| Known as | Afabicina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297501 ↗ |
| Known as | Afabicine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297501 ↗ |
| Known as | AFN-1720 | “Afabicin (formerly Debio 1450, AFN-1720) is a prodrug of afabicin desphosphono (Debio 1452, AFN-1252), a novel antibiotic in development which targets the staphylococcal...” PMID 30559136 ↗ Feb 20191“Afabicin (formerly Debio 1450, AFN-1720) is a prodrug” PMID 32747361 ↗ Sep 2020 |
| Known as | Debio 1450 | “Afabicin (formerly Debio 1450, AFN-1720) is a prodrug of afabicin desphosphono (Debio 1452, AFN-1252), a novel antibiotic in development which targets the staphylococcal...” PMID 30559136 ↗ Feb 20195“Afabicin (formerly Debio 1450, AFN-1720) is a prodrug” PMID 32747361 ↗ Sep 2020 |
| Action | Inhibit | “an enoyl-acyl carrier protein reductase (FabI) inhibitor” PMID 32747361 ↗ Sep 2020 |
| Modality | Small molecule | — CHEMBL4297501 ↗ |
| Route | Oral | “Debio 1450 40 mg, capsules, orally, once in the morning under fasted conditions” NCT02162199 ↗ |